🔗 Share this article

While America proceeds with historic changes to its vaccine guidelines, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who initially gained attention by questioning Covid vaccinations during the global health crisis and has zeroed in on possible deaths following COVID-19 vaccination in her short time at the FDA.

Proposed Changes to Pediatric Immunization Schedule

Public health authorities had intended to announce major changes to the childhood vaccine schedule in December, bringing the US with Denmark’s immunization schedule, it is understood – a significant shift that would place the US out of step with much of the international standard with little proof for improved outcomes. The announcement has been pushed back until the new year.

Rather than the director of the vaccine center, Høeg is set to address the audience at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to lead the division this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a greater focus upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for halting some childhood vaccine recommendations in the US so as to align more similar to the Danish model, a country with nationalized medicine and a citizenry approximately the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on immunizations – typically the responsibility of Prasad, head of the FDA’s CBER – instead of medication approval.

Concerns Over Qualifications

Dr. Høeg has no obvious background in medication creation, oversight or management, which has been standard for previous leaders of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the CDER, stated Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in managing a major agency. She has no expertise in industry regulation.”

Former heads of CBER would “grasp laws and regulations and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she lacks the kind of background that prior appointees who headed the center have had.”

The drug center has an vast range of responsibilities at the FDA, Woodcock pointed out.

“Many people just focuses on the innovative therapies, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and so forth, and all of those need to be looked after,” Woodcock said. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a substantial management aspect to the position, which manages over 5,000 staff members. “It is a enormous leadership role, if you execute it properly,” Woodcock concluded.

Official Statement and Contentious Initiatives

Regarding inquiries about Dr. Høeg's credentials and whether this appointment indicates more teamwork among FDA leaders on vaccines, a spokesperson stated that the “inquiries rely on inaccurate assumptions”.

“Her experience is consistent with the duties of her job,” the official said, pointing to the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg inherits the agency head's controversial expedited review system, a disputed one-day therapy clearance system that reportedly worried her predecessors. “How are these medications being chosen for this fast-track system? Who takes the choices?” Howard said. “There is a lot of secrecy happening at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards laxer regulations of most medications, except for shots.”

Established Track Record on Immunizations

With immunizations, Dr. Høeg has a more established, if problematic, history, Howard observe. She authored a analysis using unconfirmed crowd-sourced reports to estimate the incidence of heart inflammation after COVID-19 vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Part of her “desired changes” for the current administration included altering guidelines for novel immunizations and ending “non-essential” vaccines, she remarked after the election on a online show. At the FDA, Høeg has according to sources proposed preventing young men from receiving Covid vaccines.

“She’s an all-around true believer who starts off with her beliefs and tailors the evidence to accommodate the data in a very disingenuous, fraudulent fashion,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined other skeptics, {like|